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Abstract. One of the fundamental discoveries in the field of 
biology is the ability to modulate the genome and to monitor 
the functional outputs derived from genomic alterations. 
In order to unravel new therapeutic options, scientists had 
initially focused on inducing genetic alterations in primary 
cells, in established cancer cell lines and mouse models using 
either RNA interference or cDNA overexpression or various 
programmable nucleases [zinc finger nucleases (ZNF), tran-
scription activator-like effector nucleases (TALEN)]. Even 
though a huge volume of data was produced, its use was 
neither cheap nor accurate. Therefore, the clustered regularly 
interspaced short palindromic repeats (CRISPR) system was 
evidenced to be the next step in genome engineering tools. 
CRISPR-associated protein 9 (Cas9)-mediated genetic pertur-
bation is simple, precise and highly efficient, empowering 
researchers to apply this method to immortalized cancerous 
cell lines, primary cells derived from mouse and human 
origins, xenografts, induced pluripotent stem cells, organoid 
cultures, as well as the generation of genetically engineered 
animal models. In this review, we assess the development of the 
CRISPR system and its therapeutic applications to a wide range 
of complex diseases (particularly distinct tumors), aiming at 
personalized therapy. Special emphasis is given to organoids 
and CRISPR screens in the design of innovative therapeutic 
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approaches. Overall, the CRISPR system is regarded as an 
eminent genome engineering tool in therapeutics. We envision 
a new era in cancer biology during which the CRISPR-based 
genome engineering toolbox will serve as the fundamental 
conduit between the bench and the bedside; nonetheless, 
certain obstacles need to be addressed, such as the eradication 
of side-effects, maximization of efficiency, the assurance of 
delivery and the elimination of immunogenicity.
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1. The principle of the CRISPR genome engineering tool
Over the past decades, genome editing technologies have been 
composed of zinc-finger nucleases (ZFNs) and transcriptional 
activator-like effector nucleases (TALENs), empowering 
scientific results at both the basic and clinical level (1,2). 
Despite the advances that have been reported in the field of 
genomic engineering, the use of ZNF or TALEN nucleases 
is associated with several obstacles. For example, the design 
for genomic engineering techniques remains complex, and 
therefore, these techniques cannot modulate the expression 
of multiple target genes. The principle in using ZNFs and 
TALENs is protein-based and the associated toxicity is very 
high (3) (Table I), thus prompting researchers to uncover a 
novel genome engineering tool.
A novel RNA-guided endonuclease-relied genome 
editing technology that was termed the clustered regularly 
interspaced short palindromic repeats (CRISPR)-associated 
protein 9 (Cas9) system, markedly altered the landscape of 
genomic engineering (4,5). The story began with the study 
of the immune system in bacteria and archaea in an attempt 
to elucidate the mechanisms through which these organisms 
combat viral infection. In native context, it was found that 
CRISPR in combination with Cas protein provide bacteria 
with immunity against infections. Specifically, it was shown 
that the role of repeats was to recognize mobile genetic 
elements (MGEs), and thus it was possible to cut them into 
small sequences and integrate them as spacers into the genome 
of bacteria. That approach was based on the microbial immune 
system that used RNA-guided nuclease to recognize and 
cleave foreign genetic elements (6,7). In 2012, an adaptation of 
the prokaryotic immune system in mammalian cells as a gene 
editing tool was simultaneously reported for the first time by 
four different research groups [Mali et al (8), Wright et al (9), 
Jinek et al (14), Swiech et al (30)], causing a certain debate 
regarding the intellectual rights of this innovative technique. 
The newly engineered CRISPR system consisted of two 
components: A chimeric single-guide RNA (sgRNA) that 
provided target specificity and Cas9 that acted as a heli-
case and a nuclease in order to unwind and cut the target 
DNA (4,8). In this system, the only restriction for the targeting 
of a specific locus was the protospacer adjacent motif (PAM) 
sequence (‘NGG’ in the case of SpCas9) (6).
The CRISPR system was further simplified, based on its 
ability to interfere with and participate in bacterial adap-
tive immunity, comprising Cas nuclease and single-guide 
RNA (sgRNA). In general, the CRISPR system main mecha-
nism of action is mediated by the Cas nuclease, which interacts 
with DNA and generates double-strand breaks (DSBs) in 
the DNA sequence, and also matches the broken genomic 
region with a sgRNA. The sgRNA is a chimeric RNA, which 
consists of programmable CRISPR RNA (crRNA) and a trans-
activating RNA (tracrRNA) (9). Specifically, the CRISPR-Cas 
system includes a cluster of proteins, categorized into Class 1 
(Types I, III and IV) and Class 2 (Types II, V, VI) (7), all 
of which constitute specific RNA-guided DNA endonuclease 
proteins (Cas) (7,9-11). Cas proteins are driven by RNA and 
not by other proteins, to recognize the desired DNA sequence. 
The Class 2 subtype of the CRISPR system, which gener-
ally exploits Cas9 nuclease, is usually selected (9-11). The 
100 bp sgRNA forms complementary bonds with the target 
DNA sequence of 17-20 nucleotides, via Watson-Crick base 
pairing, and the tracrRNA is the component which Cas9 
nuclease binds to. Specifically, the sgRNA recognizes the 
target sequence, which is located upstream of the triplicate 
sequence named PAM, given that the PAM motif recruits 
Cas9 nuclease at site of DNA cleavage (12) (Fig. 1). Of note, 
the PAM sequence plays the determinant role in recognizing 
the correct DNA sequence and in preventing the direction 
of RNA to self-targets and non-specific sequences (13). This 
is possible as repeats of the CRISPR system do not involve 
PAM and the orientation of Cas9 depends on the PAM 
sequence (14). Overall, the genomic sequence of 14 nucleo-
tides defines the target at which Cas9 nuclease exerts its 
effects (15). More specifically, this sequence is composed of 
12 nucleotides of sgRNA in conjunction with two nucleotides 
of protospacer adjacent motif. Notably, there is a wide range 
of PAM sequences depending on their origin (16). In the case 
of Cas9 derived from Streptococcus pyogenes, the motif of 
the PAM sequence may be composed of any base, followed 
by two additional guanine bases (16).
The CRISPR system is sufficient on its own to instigate 
double helical DNA breaks, which can be repaired by non-
homologous end joining (NHEJ) or homology directed 
repair (HDR). However, the efficiency and specificity of 
the CRISPR system are not based on DNA repair mecha-
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nisms (17). In the NHEJ repair mechanism, the DNA ends 
are chemically ligated back together with a small insertion or 
deletion at the site of the break. Thus, the NHEJ mechanism is 
usually employed in cases of gene disruption (small deletions 
or insertions), inversions, duplications or deletions, whereas the 
HDR repair mechanism is used for large deletions, base muta-
tions, insertions and replacements (Fig. 2). In the HDR repair 
mechanism, a donor DNA molecule matches with the genomic 
sequence flanking the site of the DSB, thus introducing new 
genetic information into the genome at the site of the break. 
The CRISPR technique can utilize the HDR mechanism by 
using single-strand DNA oligonucleotides in order to cause 
silent mutations, thus allowing us to monitor the anticipated 
phenotype in a particular cell type (18,19). Notably, the repair 
pathway is selected based on the phases of the cell cycle; the 
NHEJ mechanism is employed in cells that are at the G1, S and 
Figure 1. CRISPR system mechanism of action. The main action of the CRISPR system is mediated by the Cas nuclease. This nuclease is recruited to DNA 
by the orientation of the PAM motif and generates double-strand breaks in DNA sequence, matching the broken genomic region with a single guide RNA. 
Following this, non-homologous end joining or homologous mediated repair mechanisms are conducted to restore the nucleotide sequence induced by double-
strand breaks, causing the anticipated genomic alterations. CRISPR, clustered regularly interspaced short palindromic repeats; PAM, protospacer adjacent 
motif; DSBs, double-strand breaks; NHEJ, non-homologous end joining; HDR, homology directed repair.
Table I. Comparison of genome engineering tools properties.
Properties ZNF TALEN  CRISPR
DNA-binding moiety  Protein  Protein  RNA
Target recognition size 18-36 nucleotides 30-40 nucleotides 22 nucleotides
Nuclease FokI FokI Cas
Toxicity  Variable to high Low Low
Complexity of design  Very complex Complex Simple
Ease of targeting multiple targets  Low Low High
Off-target effects Moderate Low Variable
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G2 phases, whereas the HDR mechanism is restricted to the S 
and G2 phases (20).
Nonetheless, the major challenge when using both 
DNA-repair mechanisms is the creation of DSBs, which can 
either trigger signaling cascades mediated by DNA damage 
checkpoints or cause the formation of gene transloca-
tions (21,22). In the case of the NHEJ repair mechanism, most 
obstacles are related to disrupting the open reading frames of 
genes, considering that the ligation of two ends after DSBs is 
error-prone. The HDR repair mechanism, on the other hand, is 
characterized by low efficiency, particularly in non-dividing 
cells, despite its high overall accuracy as a repair mechanism. 
Therefore, the CRISPR method has been modified as an 
alternative to the above repair mechanisms, using cytidine 
deaminases fused to Cas9 nickase, aiming to circumvent 
the formation of DSBs and to implement the process in 
non-diving cells. Specifically, it has been shown that the asso-
ciation of Cas9-D10A nickases mutant with apolipoprotein 
B mRNA editing enzyme catalytic polypeptide-like family 
protein 1 (APOBEC1) and uracil glycosylase inhibitor (UGI), 
leads to a 37% increase in CRISPR efficiency (23).
The homology-independent targeted integration (HITI) 
constitutes another advancement of the CRISPR system, 
as it surpasses the limitations met in both repair mecha-
nisms (NHEJ and HDR). HITI takes advantage of the NHEJ 
mechanism and aims at specific gene modifications (24). 
Characteristically, it has been documented that the most 
effective HITI rate is at 55.9% in neurons, as compared to 
HDR (1-3% efficiency) (24). These examples constitute irre-
futable evidence of the advancements that have been made in 
order to accommodate the ‘in vivo’ delivery of the CRISPR 
system, including non-dividing cells.
The structural elements of the CRISPR system through 
which Cas9 is assembled to RNA and DNA sequence include a 
T-shaped configuration comprising the four stem cell loops, the 
linker region and the repeat: anti-repeat binary complex (25). 
The formation of stem cell loops has been reported to be 
crucial for the efficiency and stability of the CRISPR-sgRNA 
complex (25).
In the field of functional studies, the CRISPR system 
has rapidly revolutionized genetic engineering, allowing 
researchers to easily alter a vast range of genomes. The 
mechanism of the pioneer CRISPR approach is based on 
RNA-DNA interaction, whereas previous genome editing 
tools (ZNFs and TALENs) were based on protein-DNA 
associations (2,26) (Table I). The properties of the CRISPR 
system that render it amenable are as follows: its simplicity in 
constructing the Cas9 nuclease and its capacity to target many 
genomic loci simultaneously. Notably, the CRISPR system 
has been distinguished over other approaches, as it enables 
the simultaneous study of numerous genetic modifications in 
one step, based on the method of multiplex target recognition, 
which uses many sgRNAs at the cellular level (27). The multi-
plex capacity of the CRISPR system is invaluable in studying 
the underlying molecular mechanisms that are implicated in 
tumor progression, given that cancer is a multistep procedure 
that involves the accumulation of genetic changes, such as 
mutations, genome rearrangements and epigenetic altera-
tions (28,29). Furthermore, the potential redundancy among 
several genes in a functional output can be delineated using 
the CRISPR method. For example, it has been shown that the 
Cas9-mediated elimination of each DNA methyltransferase 
in mouse brains highlights the role of any DNA methyltrans-
ferase in the memory compartment (30). The CRISPR system 
has proven to be efficient in inducing a wide variety of genetic 
modifications, ranging from the elimination and mutations of 
genes to genomic insertions (4,8,31,32), inversions (33,34) and 
translocations (21,32,35,36). For example, the insertion of one 
Figure 2. The use of two distinct repair pathways in performing different modifications. In the NHEJ mechanism, the ends of the DNA are chemically ligated 
back together with a small insertion or deletion at the site of the break. The NHEJ mechanism is usually employed in cases of gene disruption (small dele-
tions or insertions), inversions, duplications or deletions whereas the HDR mechanism is used for deletions, base mutations, insertions and replacements. In 
HDR, a donor DNA molecule matches with the genomic sequence flanking the site of the double-strand break and thus it can be integrated into the genome 
at the site of the break, introducing new genetic information into the genome. NHEJ, non-homologous end joining; HDR, homology directed repair; sgRNA, 
single-chimeric guide RNA.
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specific DNA template can be accomplished using HDR with 
duplex DNA templates (4,8,31,32) or single-strand oligonucle-
otides (31,37-41) or viral encoded templates (42,43). In addition, 
the Cas9 nuclease appears to be superior to other nucleases, as 
it has the ability not only to induce gain-of-function and loss-
of-function mutations, but also to cause specific modifications.
To sum up, the CRISPR technology comes with a surge of 
excitement, as it can be applied to a wide range of biological 
models, including immortalized cancerous lines, primary cells 
derived from mouse and human origins, xenografts, organoid 
cultures, as well as the generation of genetically engineered 
animal models. The CRISPR technology can be employed for 
the comprehensive dissection of oncogenic signaling pathways 
via sequential or multiplex gene editing. We envision a new era 
in cancer biology during which CRISPR-based genome engi-
neering will serve as an important link between the bench and 
the bedside. The successful implementation of sophisticated 
genetic technology aims at the comprehensive characteriza-
tion of tumors individually in patients, thus paving the road for 
the development of tailored cell-based or whole animal-based 
experimental systems.
2. The revolution in generating animal models and cell lines
Cell and animal models play an essential role in expanding 
our knowledge in the field of tumor biology. Undoubtedly, the 
use of classical biological systems is crucial for evaluating 
the efficacy of various potential therapeutic drugs. In this 
review, we analyze the mechanisms of action of the CRISPR 
system, compare it with other gene editing tools and discuss its 
contribution to the generation of genetically engineered mouse 
models (GEMMs), cell lines or organoids. The table below 
summarizes the advances achieved to date with Cas9 nuclease 
in introducing genetic changes that appear to have therapeutic 
potential in several cancer subtypes (Table II). The CRISPR 
system has been implemented not only in classical biological 
models, but also in primary cells, such as induced pluripotent 
stem cells (iPSCs), with the aim to identify novel oncogenic 
pathways and consequently novel therapeutic options against 
diverse cancer subtypes.
Genetically-engineered mouse models have been exten-
sively used in the study of tumorigenesis mechanisms and in the 
design of drugs that confer tumor resistance (44,45). Initially, 
embryonic stem cells were modified through Cre-LoxP 
homologous recombination and injected in the pro-nucleus of 
wild-type mouse blastocysts, thus rendering embryonic stem 
cells as a necessary prerequisite for the generation of geneti-
cally engineered mouse models. Consequently, sequential 
breedings were required until the animals contained mutant 
alleles (46), supporting germ-line transmission. It should be 
noted that the time for the generation of modified mice was 
approximately 9-12 months, while the insertion of multiple 
alterations was associated with a number of technical difficul-
ties. In other words, the entire process was time-consuming, 
costly and in some cases, uncertain.
In contrast to classical methods, the CRISPR system 
enables the elucidation of tumorigenesis networks and abol-
ishes the need for embryonic stem cells or time-consuming 
Table II. Cancer therapeutics arising from the CRISPR system.
Cancer type Modification Contribution to therapy Authors/(Refs.), year Journal
Breast cancer  Knock-out of Inhibition of tumor growth,  Raza et al (227), 2016 Oncotarget
 miR-644a metastasis, and drug resistance
Breast cancer  Knock-out (KO)  BC200 may serve as a prognostic Singh et al (228), 2016 Cell Death 
 BC200 lncRNA by marker and possible target  and Disease
 CRISPR system for attenuating deregulated
  cell proliferation
  in estrogen-dependent breast cancer
Endometrial Knock-out of Concomitant decrease of MUC1 and Engel et al (229), 2016 Oncotarget
cancer MUC1 at cells EGFR can be prognostic markers
 by CRISPR system in human endometrial tumors
Lung Deletion of super-  Super-enhancers
adenocarcinoma enhancers 3' to MYC stimulate cancer driver genes Zhang et al (230), 2016 Nature Genetics
and endometrial in cells by using in diverse types of cancer
carcinoma CRISPR system
Endometrial  ERα-null Inverse relationship between the tumor Kavlashvili et al (231), 2016 PLOS One
cancer endometrial suppressor PR and the oncogene
 cancer cells Myc in endometrial cancer
Prostate  NANOG and Attenuation of malignant potential Kawamura et al (232), 2015 Oncotarget
cancer NANOGP8 knockout of prostate cancer
 DU145 prostate
 cancer cell lines
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mouse breeding. The CRISPR system emerges as a reliable 
and powerful tool for the creation of mouse models that 
harbor multiple oncogenic alleles, at a low cost. With this 
technological approach, various gene networks can be targeted 
simultaneously, allowing researchers to study the synergistic 
or antagonistic effects of genes in tumor initiation and progres-
sion in an accurate and effective manner. The CRISPR system 
appears to be a major contributor to the design of mouse 
models (Table III), given that CRISPR technology can simu-
late the genetic heterogeneity of the cancer genome by creating 
indels, point mutations, large deletions, large insertions and 
chromosomal rearrangements.
The CRISPR system is invaluable in mutating, deleting, 
inserting or translocating genes. Several research groups have 
produced extraordinary results in the field of mutagenesis 
via the CRISPR approach. For example, in the modeling of 
hepatocellular carcinoma, one group managed to create a 
frameshift truncation at two genetic loci through the hydro-
dynamic injection of plasmids encoding Cas9 nuclease and 
sgRNAs (47), while another research group managed to 
generate oncogenic point mutations in the CTNNB1 gene 
with the use of homology-directed repair at DSBs induced 
by Cas9 (39). Of note, the former researchers demonstrated 
the desired modification of the phosphatase and tensin 
homolog (Pten) or p53 gene (tumor suppressor genes), alone or 
in combination, in 20 to 30% of mouse hepatocytes. Following 
the inoculation of Cas9 and sgRNAs, the authors demonstrated 
indel mutations in the Pten and p53 genes at low efficiencies of 
4 and 6.4%, respectively. Thus, it was shown that it is possible 
to disrupt gene expression in two major suppressor genes, 
causing hepatocellular carcinoma. The study produced an 
accurate and reliable model of hepatocarcinogenesis, equal to 
that provided by Cre-LoxP recombination (47). Similarly, gain 
of function mutations in oncogenes, such as the Catenin b1 
gene (Ctnnb1) were conducted at 0.5% efficiency (47). Another 
example was illustrated through the CRISPR system-mediated 
abnormal gene expression of tumor suppressor genes (Ptch1, 
Trp53, Pten and Nf1), ultimately causing medulloblastoma or 
Table III. Modeling of cancer mouse models through the CRISPR system.
Cancer type Mouse models Modifications Authors/(Refs.), year Journal
Lung  CD1 and Eml4-Alk Maddalo et al (56), 2014 Nature
adenocarcinoma C57BL/6J (B6) translocation
Lung adenocarcinoma p53+/- or p53-/- Eml4-Alk Blasco et al (55), 2014 Cell Reports
  translocation
Lung adenocarcinoma KrasLSL-G12D-/+ Nkx, Pten, Apc Sanchez-Rivera et al (61), 2014 Nature
Liver cancer FVB/NJ mice p53, Pten, Ctnb1 Xue et al (47), 2014 Nature
Pancreatic ductal  KrasLSL-G12D-/+;   Lkb1 Chiou et al (62), 2015 Genes and Dev.
adenocarcinoma R26LSL-Tom;
 H11LSL-Cas9-/+
Pancreatic ductal Kras+/LSL-G12D;  p53, Kras and p57 Mazur et al (233), 2015 Nature
adenocarcinoma Trp53loxP/loxP   Medicine
Medulloblastoma C57BL/6N mice Ptch1 Zuckermann et al (48), 2015 Nature 
    Communications
Glioblastoma  Crl:CD1 (ICR) mice Trp53, Pten, Nf1 Zuckermann et al (48), 2015 Nature 
    Communications
Breast cancer WapCre; Cdh1F/F;  Cdh1, Akt-E17K Annunziato et al (63), 2016 Resource/
 Col1a1invCAG-AktE17K-IRES-Luc/+ or Pten  Methodology
Breast cancer  Mammary stem cell  Inactivation of Zhang et al (234), 2016 Cell Reports
  (MaSC) organoid-based Ptpn22 or Mll3
 approach
Ovarian high-grade Double Trp53-/-;   Deletion at p53 Walton et al (235), 2016 Cancer
serous carcinoma Brca2-/- mutant and Brac2 genes  Research
(HGSC) mice
Invasive lobular Cdh1F/F; PtenF/F Ablation of Pten Annunziato et al (63), 2016 Genes and
breast carcinoma mice expression through  Development
(ILC)  CRISPR and lentivirus
  in mammary glands
   of mice with
  loss of E-cadherin
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glioblastoma (48). Based on these results, it appears that the 
CRISPR approach allows the genetic engineering of onco-
genes and tumor suppressor genes in specific somatic cells 
simultaneously, despite the low efficiency.
In general, specific nucleotide modifications or small 
deletions have been conducted with the use of the CRISPR 
system (31,37), thus simulating the conditions that charac-
terize specific human diseases. The CRISPR system has been 
confirmed to be invaluable in cancer research, due to its ability 
to generate cancer mouse models harboring multiple mutations 
simultaneously (49,50). For example, Findlay et al exploited 
the properties of Cas9 nuclease to create mouse models with 
distinct combinations of genetic alterations (51).
When it comes to introducing large deletions, classical 
methods have, in most cases, proven to be insufficient due to 
the many recombination events occurring in embryonic stem 
cells (52). By contrast, eliminating large chromosomal regions 
became very simple with the use of the CRISPR system, as 
indicated by the results of two research groups. Specifically, 
Yang et al introduced Cas9 mRNA and four sgRNAs into 
murine zygotes in one step, producing mice with fluorescent 
tags into the following genes: Nanog, Sox2, Oct4 (essential 
stem cell genes) and Mecp2 (which causes Rett syndrome). 
When Cas9 nuclease mRNA and two sgRNAs were specifi-
cally used against the Mecp2 gene, a 700 bp deletion was 
created (31). Additionally, the generation of germline CRISPR 
mice was accelerated by injecting CRISPR components 
in one-cell-stage embryos, as opposed to using embryonic 
stem cells, as validated by Krishnaswamy et al (53). The 
CRISPR system also proved to be very efficient inreplacing 
large ablated genomic region (exons 10-14) of dedicator of 
cytokinesis 8 (DOCK8) in Nlrp10 deficient mice (Nlrp10-/-), 
thus restoring the dynamics of the immune cell cytoskeleton 
and the dendritic cell migration, which in turn orchestrate 
the immune response (53). When it comes to introducing 
large insertions at precise locations, insertion of large DNA 
sequences has also been accomplished through homologous 
directed repair mechanism in combination with the CRISPR 
system and fluorescent tags (31).
Nonetheless, the CRISPR system does not only induce 
targeted genetic alterations, but it can also be exploited for the 
evaluation of nonsense mutations involved in tumorigenesis, as 
indicated by Billon et al (54). Similarly, Billon et al presented 
a further advancement of the CRISPR system, fusing Cas9 
nickase to base editor and constructing specific sgSTOP to 
mediate the transition of (CAA, CAG, CGA, TGG) codons 
located in the window of PAM into stop codons. The whole 
process was evaluated by restriction fragment length poly-
morphism (RFLP), through which the disruption of restriction 
enzyme recognition sites was verified (54). As a result, one can 
monitor the presence of cancer-related nonsense mutations in 
a considerable proportion (97-99%) of the eukaryotic genome 
in eight species.
Furthermore, the CRISPR system has played a fundamental 
role in the production of chromosomal rearrangements that are 
implicated in cancer progression either as ‘driver’ or ‘passenger’ 
alterations. The tumorigenic process is influenced not only by 
the presence of mutations in oncogenes or tumor suppressor 
genes, but also indirectly by the presence of ‘passenger changes’. 
For example, Torres et al accomplished the introduction 
of chromosomal translocation t(11;22)/ESWR1-FLI1 at 
percentages of 1.76 and 0.15 in 293 cells and human primary 
mesenchymal stem cells, respectively, using Cas9 nuclease and 
its related sgRNAs (32). In addition, the chromosomal translo-
cation t(8;21)/RUNX1-ETO was introduced into 293 cells and 
CD34+ human hematopoietic progenitor cells with the use of 
the CRISPR system, successfully recapitulating the phenotype 
of acute myeloid leukemia (AML). Three other research teams 
used the CRISPR approach to introduce the lung oncogenic 
gene rearrangement that results in the echinoderm microtu-
bule associated protein like 4-anaplastic lymphoma kinase 
(Eml4-Alk fusion protein). Specifically, Blasco et al used 
intratracheal or intrapulmonary lentiviral delivery of CRISPR 
components to trigger the oncogenic rearrangement between 
the Eml4 and Alk genes, located in chromosome 17 (55). 
Similarly, Maddalo et al (56) and Nishio et al (57) introduced 
the same oncogenic rearrangement using adenoviral delivery. 
In all of these studies, the experimental mice harboring the 
Eml4-Alk inversion appeared to display all the symptoms of 
non-small-cell lung cancer (NSCLC) (56) and exhibited high 
sensitivity to ALK inhibitors, such as crizotinib (57). In a 
similar setting, the CRISPR system was used to introduce the 
KIF5B-RET or EML4-ALK inversion (35), thus demonstrating 
that the proximity of two loci, in which a chromosomal 
rearrangement takes place, determines the capacity of the 
CRISPR system to reach its maximum efficiency. Last but not 
least, Ghezraoui et al successfully introduced the anaplastic 
large cell chromosomal translocation t(2;5)/NPM-ALK using 
classical Cas9 nuclease or paired Cas9 nickases (21). Cas9 
nickases are distinguished from classical Cas9 nickases due to 
one of the endonuclease domains being inactivated by a muta-
tion, which in turn confers additional efficiency.
Although the CRISPR system has been applied both to 
‘in vitro’ and ‘in vivo’ biological systems, several difficul-
ties are encountered when the Cas9 nuclease is delivered to 
the mitotic tissues of mice. The most common methods of 
transferring Cas9 along with sgRNAs consist of viral vectors 
(lentivirus, adenovirus and adeno-associated virus); even 
though adenoviruses have high packaging capacity, thus 
being able to deliver large genomic sequences (such as that 
of Cas9) (58), they may cause high immunogenic reactions 
independently of cell type (59). This has led to a combination 
of the CRISPR system and Cre-LoxP recombination technique 
in the study of the networks implicated in tumorigenesis (42). 
Specifically, Cre-dependent Cas9 knock-in mice have been 
created via incorporation of a flanked Cas9 expression 
cassette (Cre-dependent CAG-LSL-Cas9) upon the exposure 
of strong CAG promoter into the Rosa26 locus, without the 
need to package Cas9 into viral particles and the accomplished 
inducible expression of Cas9 mediated by Cre recombinase. 
The generation of Cre dependent Cas9 knock-in mice was 
the result of using the above-mentioned procedure in embry-
onic stem cells that were transplanted into the blastocysts of 
C57BL6/J mice. In turn, the Cas9 knock-in mice were trans-
duced with a cassette containing suitable sgRNAs, orientated 
towards specific yet multiple genetic loci in conjunction with 
the sequence of Cre recombinase (42). This combination of 
Cre recombinase and Cas9 nuclease was used to introduce 
loss of function mutations in tumor suppressor genes p53 and 
Lkb1 and a gain of function mutation (KRASG12D) in the 
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Kras lung gene, given that these genes are regarded ‘the driver 
cancer genes’ by the CGA Network (60). At the same time, it 
was shown that the introduction of loss of functional muta-
tions in NK2 homeobox 1 (Nkx2.1), Pten and adenomatous 
polyposis coli (Apc) genes with the CRISPR system allows for 
the creation of mouse models of lung adenocarcinoma with 
deficient p53 expression or heterozygous expression of Kras 
gene (KrasG12D-/+) through Cre-LoxP recombination (61). Thus, 
the CRISPR system was proven to be functionally significant 
in elucidating the putative drivers of signal transduction 
pathways in established mouse models of cancer. In addi-
tion, Chiou et al constructed H11LSL-Cas9/+ mice, by inserting 
the Cas9 cassette with a flanked stop region (Loxp-STOP-
Loxp) into the H11 locus of mice and they were crossed with 
CMV-Cre deleter mice, demonstrating constitutive expression 
of Cas9 due to the recombinase action of Cre. Following 
this, H11LSL-Cas9/+ mice were crossed with KrasLSL-G12D/+; 
R26LS (KT) mice, generating KT; H11LSL-Cas9/+ mice. The 
latter were infected with Lentivirus-sgLkb1/Cre with an ubiq-
uitous promoter, accomplishing the disruption of pancreatic 
Lkb1 expression in adult pancreatic cells ‘in vivo’, and thus 
simulating stages of pancreatic cancer progression (62). 
Elsewhere, Annunziato et al performed a Cdh1 gene deletion 
by encoding E-cadherin through Cre-LoxP recombination in 
mammary epithelium, with the concomitant disruption of Pten 
by the CRISPR system. Unexpectedly, the authors observed 
an increased immune response following the exposure to 
Cas9 (63).
3. Germ-line gene editing through the CRISPR system
Apart from the wide spectrum of genetic alterations, the 
CRISPR system holds considerable potential as a tool that 
can be applied to either embryonic stem cells or other types 
of stem cells, surpassing somatic mosaicism that is commonly 
found when genetic modifications are performed in zygotes. 
Genetic mosaicism has been attributed to the slow rate of Cas9 
nuclease mutagenesis and the discordance between transcrip-
tion and translation. Characteristically, it has been mentioned 
that the translation of Cas9 mRNA occurs until the first cell 
division (64). Therefore, the CRISPR system has been applied 
to embryonic stem cells for the generation of conditional 
knock-out mice. For example, Flemr et al transduced mouse 
embryonic stem cells with a vector expressing bacterial BirA 
ligase in a constitutive manner, driven by the promoter of 
the Rosa26 locus; at the same time, the cells were enriched 
with Cas9, a single-strand oligonucleotide containing the 
FLAG-AviTag sequence that could be biotinylated by BirA 
ligase and a recombination reporter equipped with (pRR-Puro) 
selection marker which was activated following homology 
recombination events (65). Thus, they established a straight-
forward and flexible method for accelerating the production 
of conditional deficient mice inessential genes, tracing endog-
enously the biallelic deficient cells without using selection 
markers (65). More importantly, they excluded the possibility 
that the phenotypes of deficient mice could be the result of 
non-targeted system efficacy.
The targeted disruption of gene expression at both alleles 
of genes Tet1, 2 and 3 in zygotes with 20% efficiency has been 
previously demonstrated (37). Following this, researchers 
attempted to disrupt the expression of five genes (Tet1, 2, 3, 
Sry and Uty); however, the elimination efficiency appeared to 
below, with the genetically modified cells constituting only10% 
of the total population. On the other hand, Wang et al (37) 
produced impressive results by introducing Cas9 nuclease 
with the appropriate sgRNAs in the germ-line of mice, thus 
managing to genetically manipulate Tet genes without the 
need for embryonic stem cells. Notably, the sgRNA can be 
delivered either as plasmid or single-strand RNA (ssRNA), 
while Cas9 nuclease can be packaged as plasmid, mRNA or 
protein. In the former approach, a concomitant introduction 
of Cas9 and a single sgRNA for each Tet gene produced 89% 
of mice harboring the anticipated genetic alterations (37). In 
the second approach, the targeting of Tet1-2 genes with the 
use of sgRNAs proved that mutations in both genes occurred 
at a percentage of 70%. In the third approach, a complex 
comprising Cas9 mRNA, sgRNA and single-strand DNA 
harboring the desirable change was used, resulting in 60% of 
the produced mice harboring one mutation and 7% of the mice 
carrying a combination of two different genetic alterations.
In the context of hematological malignancies, the proposed 
methodology includes the editing of progenitor cells ‘ex vivo’ 
and their subsequent delivery into the syngeneic recip-
ient (66-68). Hematopoietic cells have the unique capacity of 
expanding after being re-injected into the human body. For 
example, Heckl et al generated mouse models of AML by 
simultaneously altering a couple of genes in hematopoietic 
stem and progenitor cells (67). In the same context, another 
research team eliminated the tumor suppressor gene, mixed 
lineage leukemia 3 (Mll3; also known as Kmt2c), in primary 
mouse hematopoietic progenitor cells (HSPCs) of the shNf1 
genotype; Trp53-/- cells that were transplanted in AML (68). 
Impressively, it was shown that Mll3 haploinsufficiency acts as 
secondary determinant factor in the progression of leukemo-
genesis (68). Mll3 mutant mice alone did not exhibit any signs 
of leukemia, while mice harboring Mll3 mutations developed 
ureter epithelial tumors in p53+/- genotype (68).
Other studies have also documented the therapeutic 
efficiency of the CRISPR system ‘ex vivo’ in the setting of 
Eμ-Μyc lymphomas (66). Heckl et al devised a series of 
sgRNAs against eight candidate genes usually implicated in 
myeloid cancers, thereby recapitulating the proposed genetic 
networks and the mutations responsible for disease progression 
and outcome (67). Specifically, the primary HSPCs harboring 
a knock-in Flt3 internal tandem duplication (Flt3-ITD) were 
edited for five characteristic genes. These genes were either 
epigenetic modifiers, transcription factors or mediators of 
cytokine signaling and were as follows: Tet2, Dnmt3a, Runx1, 
Nf1, Ezh2, Smc3, p53 and Asxl1. The selected genes were 
modified to simulate the genetic networks responsible for the 
phenotype of myeloid malignancies (67).
Similarly, Zhong et al presented an innovative method 
for genetically manipulating AG-haESCs harboring a disrup-
tion at two distinct DNA methylated regions (H19 and Gtl2), 
thus providing evidence for the generation of live embryos 
following AG-haESC injection into mature oocytes. Of note, 
the authors demonstrated that the CRISPR genome editing tool 
successfully introduced genetic modifications in AG-haESCs, 
thus allowing genetic screening in haploid cells in a simple and 
rapid manner (69).
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4. CRISPR system: A therapeutic tool in a wide range of 
genetic diseases
With the prospect of personalized therapy, the gene editing of 
iPSCs has drawn a surge of interest in a wide range of diseases. 
The reasons behind this lie in the capacity of the cells to divide 
unlimitedly, while maintaining their genome integrity and their 
differentiation capacity into three different cell layers (endo-
derm, ectoderm and mesoderm). Notably, the use of iPSCs for 
the generation of modified cell lines appears to provide further 
insight into the underlying molecular mechanisms of each 
disease. Therefore, the autologous transplantation of iPSCs 
appears to be a promising therapy in personalized medicine, 
and the use of iPSCs in the CRISPR approach holds promise 
for the field of genetic diseases (Table IV).
Initially, Park et al supported that the CRISPR system can 
remodel the large inversions that are encountered in introns of 
blood coagulation factor VIII in hemophilia. The researchers 
corrected the mutations of the F8 gene in patient endothelial 
cells which were propagated by iPSCs. The correctness and 
accuracy of the CRISPR system was validated from the fact 
that hemophiliac mice were rescued upon the engraftment of 
corrected iPSCs (70).
In the frame of genetic diseases, gene correction seems to 
be very beneficial in hemoglobinopathies, such as sickle cell 
disease (SCD) and β-thalassemia. In the context of SCD, the 
causal origin of the disease is a replacement of valine with 
glutamate due to a homozygous missense point mutation in 
the hemoglobin subunit beta (HBB) gene, which results in the 
accumulation of hemoglobin and the circulation of red blood 
cells with conformational changes. The correction of mutated 
sickle cell gene expression was accomplished with the use of 
the CRISPR system in iPSCs derived from patients, followed 
by their differentiation into functional erythrocytes (71,72). 
It was shown that Cas9 nuclease was superior to ZNF in 
modulating the expression of the sickle gene (73). The benefit 
of the CRISPR system on SCD has also been demonstrated in 
a clinical trial (NCT03167450).
In the case of β-thalassemia, iPSCs have been shown to 
differentiate into specific lineages, thereby presenting as a 
possible therapeutic means (74). Similarly, the hemoglobin 
subunit beta (HBB) gene has been effectively engineered by 
the CRISPR approach in tripronuclear zygotes, at a 15% rate, 
considering that the mutations in the human HBB gene are 
believed to be responsible for the disease. However, the low 
effectiveness of the CRISPR approach highlighted the need 
for precise optimization in a clinical setting.
In the field of gene editing, a potential obstacle is the 
immune rejection of ‘ex vivo’ modified cells that carry newly 
expressed or corrected proteins. The infusion of modified 
cells harboring new proteins can evoke the stimulation of 
the immune system, recruiting cytotoxic T lymphocytes in 
exhausting the potential ‘enemy’. In another case, it has been 
shown that neutralizing antibodies can arise against replace-
ment blood clotting factors in patients with hemophilia (75). 
However, the possibility of inducing an immune reaction has 
been avoided with the CRISPR system, particularly if one 
considers that the gene therapy of SCD has been achieved 
without adverse effects. Specifically, autologous hematopoietic 
stem cells (CD34+ cells) have been transduced with lentiviruses 
expressing the modified globin gene, leading to the rescue of 
the phenotype at the patient level. In other words, by exploiting 
the CRISPR gene engineering tool, it was possible to alleviate 
the symptoms of the disease.
As regards Huntington's disease (HD), previous RNA 
interference-based method reduced the expression of the 
Huntingtin gene (HTT), but did not manage to completely 
attenuate gene expression, as anticipated (76). By contrast, 
the CRISPR system proved to be invaluable in eradicating 
the expression of HTT, if one considers that the origin of 
Table IV. Therapeutic approaches of the CRISPR method in a wide range of genetic diseases.
Disease gene Target Concept Substrate Authors/(Refs.), year
Hemophilia A hF8 NHEJ-mediated Patient iPSCs Park et al (70), 2015 
  correction of inversion
β-thalassemia HBB Cleave the endogenous Tripronuclear Liang et al (236), 2015
  β-globin gene (HBB) (3PN) zygotes
β-thalassemia HBB HDR-mediated correction Patient  iPSCs Xie et al (74), 2014
Cysticfibrosis CFTR HDR-mediated correction PatientiPSCs Firth et al (83), 2015
  of CFTRdeltaF508 mutation
Cysticfibrosis CFTR HDR-mediated cDNA knock-in Intestinal organoid Schwank et al (82), 2013
Cataract Crygc HDR-mediated correction Zygote, mouse SSC Wu et al (84), 2013; 
    Wu et al (85), 2015
Huntington disease HTT NHEJ mediated allele editing  Monteys et al (78), 2017
Hereditary tyrosinemia I Fah HDR mediated point  Adult tissue cells Yin et al (39), 2014
  mutation of Fah gene
Cardiovasculardisease Pcsk9 NHEJ-mediated Adult tissue cells Ding et al (58), 2014
  disruption of PCSK9
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HD is ascribed to CAG repeat expansion at the 1st exon of 
HTT. Therefore, using the CRISPR system, researchers 
have managed to disrupt the sequence of the mutant HTT 
allele (77), while at the same time another research team 
highlighted the ablation of HTT gene expression both in 
patients and in a transgenic mouse model bearing the human 
HTT, using the CRISPR system (78). In the latter case, they 
characteristically created small deletions and produced single 
nucleotide polymorphisms (SNPs), which altered the determi-
nant PAM sequence (‘NGG’), increasing the effectiveness of 
Cas9 nuclease. In both cases, the researchers used the CRISPR 
strategy to cure HD. In parallel, iPSCs derived from patients 
with HD were repaired with the aid of the CRISPR and the 
piggyBac transposon-based approach (79). In addition, in 
the case of neurogenerative diseases, such as Parkinson's 
disease, iPSCs have been employed to differentiate into 
neurons and have been used as a substrate of the CRISPR 
screen for the identification of activators of toxic protein 
a-Synuclein (aSyn) (80). In the frame of inheritable genetic 
disorders, the CRISPR approach has also been shown to 
mediate the repair of dystrophin gene mutations in zygotes of 
mdx mice (C57BL/10ScSn-Dmdmdx/J) at 2% efficiency (81).
Of note, the CRISPR approach has been used as an 
exciting therapeutic technological tool for the treatment of 
cystic fibrosis. Cystic fibrosis essentially constitutes a disease 
that is the outcome of many genetic alterations encountered at 
the CF transmembrane conductor receptor (CFTR). Organoid 
buds from iPSCs derived from patients with cystic fibrosis 
have been successfully modulated by the CRISPR system, 
holding great promise for organ transplantation and gene 
therapy (82). The correction of the CFTR locus was performed 
in a separate case, generating iPSCs with the correct allele 
of CFTR, as demonstrated by Firth et al (83). In parallel, the 
efficiency of the CRISPR genome engineering tool has been 
verified in organoids derived from patient intestinal stem cells, 
where the mutation (Phe 508) of the CFTR was repaired (82). 
It should be mentioned that the elimination of the side-effects 
caused by the CFTR mutation was verified via normal secre-
tory functions (82). Apart from the repair of the CFTR locus 
in stem cells of various origins, studies have supported the 
CFTR gene editing in one step, upon influx of the CRISPR 
system in zygotes. In such cases, an oligonucleotide of wild-
type CFTR sequence is inserted as a donor template and used 
by the Cas9 nuclease via homologous recombination (84). The 
results were profoundly spectacular due to germ-line transmis-
sion of the repaired CFTR locus allele, even though off-target 
mutagenesis remained a possibility. Nonetheless, the danger 
of insertional mutagenesis in murine germ-line cells was 
abrogated by engineering the mutant loci at spermatogonial 
stem cells (SSCs). Wu et al reported that the mutational repair 
of the EGFP transgene or endogenous Crypc gene via the 
CRISPR approach in SSCs that were competent to form male 
gametes after injection into testes, resulted in the formation of 
round spermatids following fusion with mature oocytes (85). 
The major advantage of genetic manipulation via the CRISPR 
approach in SSCs, as compared to gene editing in zygotes, has 
been the lack of side-effects and the generation of anticipated 
descendants at 100% efficiency (85). Therefore, the CRISPR 
method has proven to be a promising approach for the treat-
ment of genetic diseases.
In addition to the above-mentioned findings, Xie et al (86) 
demonstrated that the epigenetic dormancy of the FMR1 gene 
was reversed using the revolutionary genome editing tool, 
CRISPR in iPSCs derived from patients or in somatic hybrid 
cell lines. The effect of Cas9 was directed to the removal of 
the CGG repeats that are encountered in the FMR1 gene. 
Specifically, the researchers cleaved the FMR1 gene repeats 
with high efficiency, inducing DSBs and using homologous 
recombination (86). The same genetic disorder was also 
reported to be repaired via NHEJ, albeit less efficiently (86). 
A landmark study by Horii et al successfully demonstrated 
the genetic correction of a mutation at the DNMT3B locus in 
iPSCs with the use of the CRISPR system, thus repairing a rare 
abnormality [termed immunodeficiency centromeric region 
instability facial anomalies syndrome (ICF)] (87). In the pros-
pect of curing human severe immunodeficiency, researchers 
observed that iPSCs deficient for JAK3 perished during the 
initial stages of the disease due to a low BCL2 expression 
pattern; nonetheless, the correction of the JAK3 mutation 
with the CRISPR approach caused iPSCs to differentiate into 
fully functional T cells, including the full spectrum of T cell 
receptors (TCRs) (88). Consequently, the combination of the 
CRISPR approach and iPSCs has been reported to be particu-
larly beneficial in chronic granulomatous disease (CGD), 
where patients suffer from the accumulation of oxidative 
molecules that are used as a phagocytic weapons against fungi 
and bacteria (89).
Furthermore, patient-derived pluripotent stem cells 
have been exploited by the CRISPR method for therapeutic 
intervention in other diseases, such as Fanconi anemia (90), 
dominant dystrophic epidermolysis bullosa (91), retinitis 
pigmentosa (92) and severe cases of retinal dystrophy [Leber 
congenital amaurosis-10 (LCA10)] (93).
Finally, the CRISPR system has been highlighted as a unique 
system with profound impact on repairing gene mutations in 
adult tissues ‘in vivo’. Yin et al (39) rescued the phenotype 
generated by Fah gene deficiency via repairing of the Fah 
mutation in hepatocytes using the CRISPR system. Notably, 
Cas9 nuclease mediated its beneficial action by restoring the 
function of hepatocytes at very low (0.4%) efficiency in mouse 
models harboring hereditary tyrosinemia (39). Despite the 
initial effectiveness of the genome engineering tool being very 
low, it was culminated over time, repairing 33% of deficient 
hepatocytes. In another experimental setting, the disruption of 
Pcsk9 gene expression in the liver resulted in an attenuation of 
the concentration of LDL-C, which would otherwise be very 
harmful for the heart (58).
As a general note, it has been claimed that the Cas9 
nuclease constitutes a therapeutic model for the treatment of 
several genetic disorders. In the case of monogenic recessive 
disorders, such as cystic fibrosis, sickle-cell anemia, hereditary 
tyrosinemia or Duchenne muscular dystrophy, the target muta-
tion can be repaired with the aid of Cas9. In this manner, the 
protein derived from the corrected gene can be developed in 
native conditions. In the case of dominant-negative disorders 
where the target gene is represented by one allele (haploin-
sufficiency phenomenon), the CRISPR system seems to be 
the most advantageous method in inactivating the mutated 
allele. Alternatively, the use of inactivated Cas9 fused to a 
transcriptional repression domain can be used to rescue the 
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phenotype (94). In addition, the elimination of duplicated 
regions could be accomplished through Cas9 nuclease and 
NHEJ-mediated repair, whereas therapeutic benefit has also 
been observed by introducing protection mutations in mitotic 
tissues in complex diseases. Finally, the CRISPR system has 
been employed in the modification of T cells, particularly with 
chimeric antigen receptor (CAR) or artificial TCRs, prior to 
introducing them into the body of cancer patients (95) (Fig. 3).
5. Organoids: Smart weapons against complex genetic 
diseases
A significant part of the research community has focused on 
the generation of the reliable biological models (animal and 
cell lines) that will be able to mimic all the characteristic 
mechanisms of cancer cells with high fidelity. In many cases, 
the complete understanding of the genetic perturbations 
involved in cancer outgrowth has been accomplished; however, 
researchers have been unable to directly modify genes in the 
human body, thus resulting in a highly anticipated therapeutic 
strategy (96).
Despite the successful creation of GEMMs, there is 
significant shortage of therapeutic applications, mainly due 
to difficulties in the isolation of specific neoplastic cells from 
the multitude of extended stromal compartments in animal 
models. The scarcity of therapies can also be explained by 
the fact that animal models are time-consuming and costly. 
Cancer cell lines, on the other hand, are known to harbor 
genetic profiles that are not identical to the initial tumor mass 
and are cultured in two-dimensional directions. Furthermore, 
cancer cell lines are uncoupled to the amount of non-neoplastic 
cells, which are usually located in the tumor microenviron-
ment (97). As a consequence of the above, organoids have 
been postulated as a novel facile tool that holds great promise 
in the field of cancer research. Tumor-derived organoids can 
mimic all the typical characteristics of the initial tumor mass, 
the three-dimensional (3D) structural framework and the 
property for uncontrolled growth. It has therefore been shown 
that organoids can not only recapitulate the genetic modifica-
tions that arise in cancer cells with high fidelity (98), but can 
also provide unique opportunities for the generation of fully 
characterized models at an unprecedented rate.
Hans Clevers and colleagues were the pioneer investigators 
in the field of organoids, as they managed to create intestinal 
epithelial organoids with distribution of all cell types (such as 
stem, goblet and villus cells), maintaining the procedures of 
cell division and differentiation in physiological conditions 
[Sato et al (99)]. Hans Clevers supported that organoids are 
able to efficiently simulate the tissue microenvironment, as 
represented by their structural and functional hallmarks (100). 
Lancaster and Knoblich, on the other hand, defined an 
organoid as a 3D structure in which progenitor cells are self-
organized in order to commit to specific cell lineages, in a 
manner which is consistent with the ‘in vivo’ conditions (101). 
Characteristically, the cells of organoids have internal gates of 
self-assembling and self-regulation, even though their manipu-
lation is not restricted to exogenous signals.
The origin of organoids can be either embryonic or adult 
stem cells or patient-derived stem cells (100). On the one 
hand, organoids derived from stem cells can be crucial to the 
study of organ development or organ pathologies (101). While 
pluripotent stem cell-based organoids exploit developmental 
processes, adult stem cells can be coerced to form organoids 
by creating conditions that mimic the stem cell environment 
during physiological tissue self-renewal or during DNA 
damage/repair (102). On the other hand, patient-derived organ-
oids can be used to gain drug-response feedback in patients. 
Tumor organoids display a differential mutational landscape 
indicative of each parental tumor. The feasibility of culturing 
solid tumors directly from the patient in the form of organoids 
holds great promise (102).
From a functional aspect, the generation of human organ-
oids is regarded highly important, as it has the potential to 
enable the study of human pathogenesis ‘in vitro’. For example, 
murine neoplastic organoids have been generated from Kras+/
LSL-G12D; Pdx1-Cre mice (‘KC mice’) in order to recapitulate 
the phenotype of human preinvasive pancreatic intraepithe-
lial neoplasms (PanINs) and Kras+/LSL-G12D; Trp53+/LSL-R172H; 
Pdx1-Cre mice (‘KPC mice’) (103). It was demonstrated that 
many candidate driver genes of the neoplastic procedure 
are represented in the proteomic and transcriptional genetic 
profile of murine pancreatic ductal organoids (103). The 
functional significance of organoids was demonstrated when 
human tumor organoids were engrafted into immunocompro-
mised (Nu/Nu) mice, thus highlighting the presence of the 
stromal compartment and validating the accuracy of pancre-
atic tumorigenesis through organoids (103).
Nonetheless, the use of organoids is not restricted to the 
study of molecular mechanisms that drive developmental 
processes (104,105), but may also be used for the modeling 
of diseases (Fig. 4). At the same time, the generation of 
patient-derived organoids can serve as an ‘ex vivo’ rational 
platform that has the potential to predict the patient response 
to specific drug administration, thereby helping towards 
deciding on the appropriate patient treatment individually, 
particularly if one considers that the majority of organoids are 
amenable to pharmacological studies (Fig. 4). For example, 
van de Wetering et al used patient-derived organoids as a 
potential model to simulate the networks that characterize 
intestinal diseases, submitted them in high-throughput drug 
screens, thereby investigating the interactions among target 
genes (106). Intestinal cancer organoids derived from 20 
sequential colorectal carcinoma patients were employed to 
create a living colorectal biobank (106), given that conven-
tional cancer cell lines do not represent the tissue structure 
and genetic characteristics of original neoplasms. Remarkably, 
the differential expression of parental intestinal neoplasms 
was well detected in colorectal organoids (106) and was 
shown that colorectal tumor organoids retained the molecular 
and histopathological features of original tumors, as well as 
their transcriptional profile. Importantly, van de Wetering et al 
demonstrated the existence of an association between drugs 
and the genomic profile of tumor organoids. Furthermore, p53 
gene-deficient tumor organoids appeared to be prone to treat-
ment with the MDM2-inhibitor, Nutlin-3a, whereas organoids 
with the elimination of RAS mutations were respectively 
sensitive to therapy with specific antibodies against epidermal 
growth factor receptor (EGFR) (106). Consequently, the 
pharmacodynamic profile of primary cancers, as well as of 
infectious and developmental diseases, has the potential to 
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Figure 3. Cas9 nuclease as a therapeutic model for the treatment of genetic disorders. In the case of monogenic recessive disorders such as cystic fibrosis, 
sickle cell anemia, hereditary tyrosinemia or Duchenne muscular dystrophy, the target mutation is repaired with the aid of Cas9. In this manner, the protein 
derived from corrected gene can be developed in native conditions. In the case of dominant-negative disorders in which the target gene is represented by one 
allele (haploinsufficiency phenomenon), the CRISPR system seems to be the most advantageous method in inactivating the mutated allele. In other instances, 
the elimination of duplicated regions could be accomplished through Cas9 nuclease and NHEJ mediated repair, whereas therapeutic benefit has also been 
observed by introducing protection mutations in mitotic tissues in complex diseases. Finally, CRISPR system has been employed for the modification of T cells, 
especially with CAR or artificial TCRs, with the aim to introduce modified cells into the body of cancer patients. CRISPR, clustered regularly interspaced 
short palindromic repeats; Cas9, CRISPR-associated protein 9; NHEJ, non-homologous end joining; CAR, chimeric antigen receptor; TCR, T-cell receptor. 
The single asterisk (*) indicates cystic fibrosis, sickle cell anemia or Duchenne muscular dystrophy. The double asterisks (**) indicate transthyretin-related 
hereditary amyloidosis or dominant forms of retinitis pigmentosum.
Figure 4. The use of CRISPR-edited organoids. CRISPR gene editing can be used to generate organoids for drug target validation, mechanistic analysis and 
patient stratification studies,as well as high-throughput pooled or high-content arrayed screens. CRISPR, clustered regularly interspaced short palindromic 
repeats; PAM, protospacer adjacent motif; iPSCs, induced pluripotent stem cells.
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be recapitulated from a colorectal biobank derived from 
organoids that have originated from patient biopsy samples, 
thus aiding in the conduction of personalized therapy that is 
pertinent to genes of drug sensitivity or resistance.
The potential use of organoids in the field of transplantation, 
as an alternative to iPSCs, holds immense promise. Organoids 
have been transplanted in an autologous manner without 
immunogenicity reactions, without the risk of teratomas and 
with assured stability (107). Notably, researchers have found 
the culture conditions for gastric (108), pancreatic (109), 
hepatic (110), prostatic (111,112) and intestinal organoids (113). 
The ultimate goal is to replace damaged organs inpatients 
with organoids that do not harbor the usual genetic perturba-
tions, given that the colonization of cancer organoids in the 
human body can contribute to metastasis (60,114,115). A 
feasible personalized approach can be performed through 
the correction of genetic modifications by Cas9 nuclease in 
patient-derived organoids, and subsequently, the transplanta-
tion of these modified organoids into the bodies of patients. 
Nonetheless, the engraftment of organoids and the delivery 
of Cas9 nuclease and its components need to be further 
optimized, as thus far, the engraftment of organoids has been 
accomplished at only 1% efficiency, whereas a 10% efficiency 
is usually required for the replacement of determined protein 
elimination, as shown in the case of liver organoids (110).
From a therapeutic point of view, the use of organoids and 
their genetic manipulation through the CRISPR system is 
regarded extremely important in precision medicine. Recently, 
a colorectal tumor organoid library (CTOL) was constructed, 
encompassing 55 colorectal tumor organoids and 41 respec-
tive normal colorectal organoids (116), using the CRISPR 
approach. Fujii et al (116) demonstrated that the transition of 
carcinoma to more progressive stages was not associated with 
niche signals; at the same time, it was suggested that the muta-
tions in oncogenic pathways are responsible for conferring the 
selective advantage of neoplastic growth, thus paving the way 
for the development of patient-specific therapies. Personalized 
therapy based on organoids seems feasible if one considers 
the reported mutations of the main five signaling pathways: 
WNT, RAS/mitogen-activated protein kinase (MAPK), 
phosphoinositide 3-kinase (PI3K), transforming growth 
factor (TGF) and p53 (60). The study by Fujii et al provided 
compelling evidence that tumor organoids and the CRISPR 
approach can be effectively used in xenotransplantation assays 
‘in vivo’, thus bridging the gap between genetic profile and 
personalized medicine. Specifically, organoids were injected 
in splenic compartments or into renal cell types of NOG mice, 
demonstrating that the drivers of metastatic process are not 
related to mutations or niche requirements (116). Additionally, 
Fujii et al managed to modify genes of interest in organoids 
derived from patient colon tissue using the CRISPR approach, 
in an attempt to elucidate the functionality of intestinal cell 
types. Last but not least, the powerfulness of the CRISPR 
approach was confirmed by Drost et al (117), via sequential 
editing of genetic loci Apc, p53, KRAS and SMAD4 and 
converting normal colon organoids derived from human intes-
tinal crypt stem cells to tumor organoids, without the need for 
stem-cell niche factors. Characteristically, it was shown that 
APC and p53 deficiency can induce chromosomal instability 
and aneuploidy, i.e., characteristics of cancer. The efficiency 
of tumor organoids was mostly highlighted by the fact that 
they sustained their tumor heterogeneity upon engraftment 
into immunodeficient mice (117). The innovative results 
were attributed to the plasticity of stem cell organoids, which 
undoubtedly expand our understanding of the underlying 
molecular mechanisms responsible for colorectal carcinogen-
esis.
Overall, it is considered that organoids can function as 
smart weapons against many cancer types, by the release 
of soluble proteins with immunomodulatory activity or 
recombinant antibodies lacking Fc, with modified proper-
ties, thus circumventing the cytokine storm induced by the 
cross-reaction of cells bearing Fc receptors (118,119). Thus, 
cells are precisely committed to continuously providing 
immunotherapeutic molecules against cancer. The rationale 
is based on allowing cells to be developed in a constrained 
and controlled environment, secreting therapeutic molecules 
when the cancer cells are present. For example, organoids 
constructed by mesenchymal stem cells have been mentioned 
to secrete interleukins (IL-2, IL-12), thus preventing the onset 
of melanoma (120,121).
Even though tumor CRISPR-modified organoids hold great 
promise for gene therapy in a number of diseases, their use 
may be hindered by certain disadvantages, as shown in the 
case of intestinal tumor organoids. For example, drug side-
effects cannot be properly evaluated as intestinal organoids 
lack immune, nervous and vascular system (122,123). In 
addition, heterogeneity is usually observed between human 
and murine organoids, which can be ascribed to the existence 
of secreted factors in the intestinal microenvironment, as for 
example epigenetic factors, hormones, etc. Finally, in certain 
cases, the composition of organoids is not consistent with the 
structure of cells naturally occurring in an organism (124).
6. Applying bioengineering approaches and creating the 
appropriate niche to improve organoid-based therapies 
‘in vivo’
Organoids, despite attempting to simulate the proxies of ‘in 
vivo’ tissues, they do not recapitulate the complexity of an 
organism. The whole procedure of generating organoids 
requires optimization at many levels. First of all, a specific 
extracellular matrix (ECM) is a prerequisite for various cell 
types, considering that the ECM is the driver of signaling 
and responsible for the structural landscape (125). Matrigel is 
usually used for the engraftment of stem cell-derived organ-
oids; however, it is not sufficient in meeting the requirements 
in a cell type-dependent manner (126). Several approaches 
have been used for the deposition of specific ECM in 
various cell types, such as nanolithography, soft lithography, 
electron-beam, nano-imprint lithography, etc. (127), which 
mimic the basement membrane fibers. Another method for 
constructing natural organoids is to design surfaces that 
ensure the engagement of adhesion molecules. However, the 
regulation of signaling cues in a spatial-dependent manner 
poses a significant challenge when it comes to natural engraft-
ment of organoids into organisms. The delivery of soluble 
growth factors with the use of nanoparticles or bioresponsive 
materials can confer the control of signal orchestration in a 
spatial-dependent manner (125). Finally, it should be taken 
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into consideration that other cell types, such as immune 
and mesenchymal cells, can play a fundamental role in the 
successful engraftment of organoids, as it has previously been 
shown by Lindemans et al (128). In the same context, luminal 
cells have been shown to play a vital role in conducting the 
necessary interactions between microbial flora and epithelial 
cells, as well as cells of the epithelial layer (129).
7. Towards personalized therapy
The comprehensive understanding of the molecular alterations 
that have a profound impact on gene expression is essential in 
order to achieve personalized care for patients with neoplasia. 
Undoubtedly, personalized medicine has already been used 
by clinicians (130). The national scheme of clinical trials will 
enable clinicians to determine the appropriate drug adminis-
tration for each patient individually and the CRISPR approach 
has the capacity to confer additional therapeutic benefit.
A recent study demonstrated that patient-specific therapy 
can bypass the drug resistance that is usually associated with 
lung cancer and is caused by tyrosine kinase inhibitors (TKIs) 
targeting against EGFR. Genomic mutations in EGFR (Ε19del, 
T790M at exon20 and L858R) have been highly associated 
with the drug resistance of lung tumors following the admin-
istration of TKIs, particularly the T790M mutation, which 
is found in >50% of patients. In this context, Cas9 nuclease 
emerges as a molecular scalpel that can modify the genome in 
such a manner that the outcome of the disease is improved in 
a personalized and permanent manner. The proposed proof of 
concept is the repair of the mutated EGFR gene, using Cas9 
nickase. Specifically, Cas9 nickase can either induce single-
strand breaks and repair the mutated gene via homologous 
recombination (HDR), or decay the mutated EGFR. It has been 
postulated that CRISPR component assembly can be achieved 
in plasmids and delivered intratracheally or intravascularly in 
some cases (131).
8. The contribution of functional genome-wide pooled 
sgRNA screens
The rarity of experimental results derived from animal 
models or immortalized cell lines has led researchers to 
conduct observational studies, such as genome-wide associa-
tion studies (GWAS), in order to identify genes are strongly 
associated with disease onset. Data from numerous studies 
[The Cancer Genome Atlas (CGA) (132), the Cancer Cell 
Line Encyclopedia (CCLE) (133) and the Encyclopedia of 
DNA Elements (ENCODE) (134)] were previously collected 
to provide deeper insight into the association of genes with 
disease predisposition (132-134); however, they were proven 
to be insufficient. Respectively, genome-wide loss-of-function 
screens employed RNAi approaches, but they did not prove to be 
particularly beneficial due to the partial knockdown of prede-
termined genes, random side-effects and their propagation in 
protein-coding genes (135). Therefore, despite the accumula-
tion and reliability of the existing results, the researchers were 
unable to discriminate which genetic variants are implicated 
in particular disease phenotypes. The recent generation of 
unbiased genome-wide functional CRISPR screens has identi-
fied the functional role of thousands of genomic elements in 
parallel, irrespective of their position in the coding or non-
coding compartment. In addition, CRISPR screens have been 
used for both the positive and negative selection of genes that 
are usually implicated in tumorigenesis.
As regards the construction of sgRNA libraries mediated 
by the CRISPR system, it has been noted that the principles of 
constructing large scale screens are as follows: i) The use of 
cloning tools for the pooled synthesis of sgRNAs (135-137); 
ii) the design of three up to ten sgRNAs that mark a specific 
gene (135); and iii) the consistency of Cas9 nuclease and its 
relevant sgRNAs. In brief, libraries are produced as DNA 
and are incorporated into plasmids via cloning to generate 
lentiviruses (138). The pool of sgRNAs (represented by 
oligonucleotides) often targets 104 to 105 different genes 
and multiple sgRNAs are designed to augment the accuracy 
at specific target genes. In addition, lentiviruses expressing 
Cas9 nuclease and sgRNA are delivered at a low multiplicity 
of infection (MOI), enabling a single sgRNA to be introduced 
into the cell (138). At the end of the procedure, the lentiviral 
library of sgRNAs is amenable to phenotypical tests and 
high-throughput sequencing in order to identify and classify 
the gene targets that are enriched or diminished in various 
conditions (139). Despite the advances in designing pooled 
libraries, certain biases have not been circumvented, such as 
library synthesis and defaults during experimental procedures, 
such as cloning.
When it comes to the classification of CRISPR screens, they 
can be subdivided into CRISPR nuclease screens (CRISPRn 
screens), CRISPR interference screens (CRISPRi screens) 
and CRISPR activation screens (CRISPRa screens). The main 
differences between the CRISPRn and CRISPRi screens are 
as follows: In CRISPRn screens, Cas9 nuclease targets any 
gene surrounded by a PAM sequence, causing its elimina-
tion. For example, CRISPRn screens have been used in the 
identification of significant developmental genes (135), as 
well as genes implicated in cancer growth (140). However, 
the results have not been particularly encouraging, due to the 
restricted number of cells (141) and the phenotypes following 
inactivation of the anticipated gene, possibly resulting from 
in-frame insertion/deletions (INDELs) and hypomorphic 
alleles (142). These pitfalls have led scientists to the revela-
tion that CRISPR screens can be modified to included Cas9 
using CRISPR interference (CRISPRi) (143). Thus, CRISPRi 
screens, which conjugated dCas9 with different transcriptional 
repression domains, accomplished highly efficient transcrip-
tional silencing (144,145) in any given cell type, including 
iPSCs (146). In general, the effects mediated by CRISPRi are 
more efficient, rapid, specific and homogenous as opposed to 
those caused by Cas9 nuclease. The only difficulty associated 
with CRISPRi screens is that dCas9-KRAB inhibits gene 
expression only when sgRNA is targeted to the transcrip-
tion start site (TSS) of a gene (145). Overall, the efficacy 
of CRISPR interference has been shown to be significantly 
affected by certain parameters, such as the length of sgRNA, 
the sequence complementarity, the distance of target gene 
from transcriptional start site (TSS) and the chromatin state 
constitute the factors that influence the power of CRISPRi. 
The minimal length of sgRNA for efficient silencing should 
be 12 nucleotides, whereas the minimum length of PAM 
should be two nucleotides (143). Theoretically, the genomic 
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sequence that can be targeted by Cas9 for efficient silencing 
should be 268 Mb (414). The specificity is dictated by two 
PAM nucleotides and 12 nucleotides between the sgRNA 
and DNA stretch, indicating that the alteration, on average, of 
one PAM nucleotide is efficient to abolish CRISPR interfer-
ence (143). Notably, CRISPRi is the most effective when the 
sgRNAs targeted a region of 150 bp downstream or upstream 
of the TSS (145).
dCas9, coupled with multiple copies of the activator 
effector domain, have also been used, thereby accelerating the 
transcriptional enrichment of the gene of interest and inducing 
the generation of CRISPRa screens (145). In this manner, 
CRISPRa screens have the potential to elucidate phenotypes 
based on the overexpression of certain genes (145), thus 
offering advantage over the previously used cDNA screens 
that included elaborate design of cDNAs. An additional 
advantage of CRISPRa screens over cDNA screens is that 
they induce transcriptional expression even from secondary 
transcriptional start sites, particularly if one considers that 
the design principle of sgRNAs is based on targeting any 
sequence with a transcriptional start site that is surrounded 
by a PAM sequence. For example, novel CRISPRa screens 
have been designed, conjugating dCas9 with distinct tran-
scriptional activators in order to search for gain-of-function 
phenotypes (147,148). Nonetheless, CRISPRa screens cannot 
be used to stimulate the expression of highly repressed genes. 
Another method includes fusing dCas9 to different domains 
of epigenetic modifiers, as an attempt to elucidate the effects 
of epigenetic modifications on chromatin states. Using trun-
cated sgRNAs or building redundancy with several sgRNAs 
targeting each locus, constitute important design principles for 
filtering out false positive signals and improving the interpret-
ability of screening data.
sgRNA libraries were first employed for the identification 
of novel target gene high-confidence biomarkers, thus aiding 
in the design of innovative therapeutic options. At a genome-
wide level, CRISPR knock-out libraries were constructed 
to show sensitivity or resistance to classical therapeutic 
inhibitors (6-thioguanine and vemurafenib), thus revealing 
novel drug resistant genes (135,136). For example, deficient 
libraries (termed Cas9 knockout-GeCKO libraries) were 
constructed using sgRNAs with the aim of identifying driver 
genes, whose loss confers resistance to the classical therapy 
of melanoma, using the BRAF inhibitor, vemurafenib (135). 
In the same context, a loss of function CRISPR library was 
generated at the genome-wide level in order to identify 
genes that were involved in uncontrolled cell growth and 
pluripotency (135). Following this, the candidate genes were 
engrafted into mice and generated tumor formation, demon-
strating their functional significance in metastasis. In the 
same context, another CRISPR-mediated screen eliminated 
candidate genes that were downregulated in Ara-C resistant 
AML cell lines and highlighted the functional significance 
of Dck as the primary contributor conferring resistance to 
the chemotherapeutic Ara-C (149). Tzelepis et al provided 
convincing evidence regarding the functional sensitivities and 
potential therapeutic targets in five cell lines that mirrored 
the transcriptional landscape of AML: MOLM-13, MV4-11, 
HL-60, OCI-1ML2 and OCI-AML-3. As a result, the KAT2A 
molecule (histone lysine acetylatransferase-SAGA member) 
was identified as a therapeutic target of utmost importance. 
The therapeutic potency of KAT2A was confirmed in an ex 
vivo leukemia mouse model (Rosa26; Flt3ITD-/+ with the 
retroviral infection of MML-AF9 or MLLAF4), further 
demonstrating its harmless nature in normal hematopoietic 
cells (150). Respectively, the sensitivity of certain genes 
to ATR inhibition (151) and p53 expression status (152) on 
a genome-wide and high-throughput level using CRISPR 
screens was also demonstrated.
The benefits of CRISPR-based screens are not restricted to 
the identification of genes that are implicated in drug resistance 
and tumorigenesis; their use also expands to the study of the 
genomic alterations that confer resistance to classic therapeutic 
options. When it comes to elucidating the genomic alterations 
that cause tumor resistance, researchers have used the CRISPR 
approach to identify nucleotide alterations (including kinesin-5 
A133P mutation or exportin-1 cysteine 528 residue) that confer 
loss of sensitivity to classic clinical drugs, such as Ispinesib 
(an inhibitor of kinesin-5) in osteosarcoma therapy (153) and 
Selinexor (inhibitor of exportin-1) in multiple myeloma (154). 
Last but not least, Steinhart et al used CRISPR screens in 
RNF43-mutant pancreatic ductal adenocarcinoma (PDAC) 
cells, identifying novel therapeutic targets and opening up new 
avenues for antibody generation (155).
Zhu et al modified CRISPR screens in a manner that 
paired guide RNAs were used to ablate regions of long non-
coding RNAs of 700 bp in length, as the indel mediated by one 
sgRNA was insufficient to cause loss-of-function phenotype. 
Using this particular method, 700 lncRNAs in the human 
genome were screened, taking into consideration that the 
careful design of guide RNAs is a prerequisite for avoiding 
overlap with other functional elements (156). Undoubtedly, the 
optimization of the procedure is essential for the identification 
of the underlying mechanisms of action of non-coding RNAs, 
as the modified method could be amenable to other regula-
tory elements, such as microRNAs. In other words, unbiased 
genome-wide functional screens can be used to dissect new 
enhancers and other regulatory elements that have profound 
impact on the protein level.
Jaitin et al reported a method in which single-cell RNA 
sequencing (RNA-seq) was combined with CRISPR-pooled 
screens in an attempt to decipher the regulatory circuits of 
myeloid development. Specifically, they constructed lenti-
viral backbones, each of which was composed of a sgRNA 
expression cassette, transcribed UGI (unique guide index) and 
the fluorescent selection marker. The concept was based on 
tracing each sgRNA located in CRISPR-pooled screens, taking 
into consideration the expression pattern of unique guide 
index (UGI) and the data acquired by single-cell RNA-seq. 
The presence of fluorescent marker aided in the selection of 
cells. In other words, the researchers implemented the method 
such that they managed to compare fluorescent densities with 
transcription modules, as represented by UGI read counts, thus 
highlighting the factors involved in developing the distinct 
immune subpopulations and delineating the genotype-to-
associations in single cells. The results supported that Cebpb 
was the determinant factor controlling the differentiation of 
myeloid cells to either dendritic or monocyte cells. In the case 
of Cebpb deficiency, Irf8 played a vital role in the dendritic 
cell differentiation route (157).
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9. The combination of immune and CRISPR system against 
complex diseases
Immunotherapy has arisen as a novel method in the treatment 
of cancer. Tumor-specific T cells can be modulated and infused 
into the body of patients suffering from synovial cell sarcoma, 
lymphoma or melanoma or leukemia (158), with significant 
implications in personalized therapy.
A recent immunotherapy breakthrough was based on 
the use of CARs, which bind to specific antigens in cancer 
cells (159). These receptors have attracted much attention as 
they can be very easily engrafted in any patient, circumventing 
any possibility of immunogenicity. Evidently, the concept is 
based on the complete matching of CAR on T cells with the 
antigen of cancer cells, with the aim of eliminating cancer 
cells. In the past, genetically edited CAR-T cells produced 
by ZFNs, TALEN nucleases did not yield the desired results. 
Nowadays, T cells can be reprogrammed using the CRISPR 
gene-manipulating system and can be used to eradicate 
leukemia cells or to treat patients with relapsed B-cell malig-
nancies in remission. For example, Eyquem et al demonstrated 
that Cas9-modified effector T cells displayed CD19-specific 
CAR receptor, recognizing the specific sequence of T cell 
receptor alpha constant (TRAC) and successfully treating 
acute lymphoblastic leukemia in a mouse model (160). In this 
manner, outpaced modified effector-T cells proved to be very 
efficient in recognizing antigen following repeated exposures, 
and prevented the expansion of cancer cells as well as exhaus-
tion of T cells. In parallel, certain pharmaceutical companies, 
including Novartis, have used the CRISPR technology in 
CAR-T cells in order to decipher the most suitable therapeutic 
application in each cancer type. Following approval from the 
Recombinant DNA Advisory Committee at the US National 
Institutes of Health, clinical trials have been conducted on 
castration-resistant prostate cancer, muscle-invasive bladder 
cancer, lung cancer and metastatic renal cell carcinoma, using 
CRISPR technology (161).
Α cornerstone strategy in the field of cancer immuno-
therapy is the abrogation of ‘immune checkpoints’, such as 
PD-1 and CTLA-4. The principle is based on PD-L1 binding 
expressed by cancer cells at the PD-1 receptor in chronically 
activated or exhausted T cells, leading to an exacerbation of 
cancer cell growth and in turn compromising the anti-tumor 
immune effect of activated T cells against cancer cells, through 
engagement of PD-1 receptor to the PDL-1 molecule (162). For 
this reason, in an attempt to couple the ‘immune check-point’ 
and the CRISPR system, researchers have produced RNP 
complexes composed of sgRNA and Cas9 (Cas9 RNPs), as 
well as single-stranded DNA oligonucleotides as a template 
for homology-directed repair to replace the expression of PD-1 
in human primary T cells, rendering them more effective (40). 
The same research team employed Cas9-RNA RNPs to 
introduce knock-in modifications in the CXCR4 coreceptor of 
human primary T cells in the face against HIV infection (40). 
Undoubtedly, the particular research study became a landmark 
in T cell genome engineering, presentinga fast, efficient and 
very safe method of modulating primary immune cells, as 
Cas9 RNP complex delivery was reduced to 24 h, with signifi-
cant implications in the amelioration of side-effects. Cas9 
RNP technology needs to be improved due to the low rate of 
the resulting modifications (20%), following the enrichment 
of FAC-sorted cells with low protein expression. In addition, 
one should take into consideration that the efficiency of T cell 
editing can be affected by the dynamics of their chromatin 
state, their activation potential or other exogenous signals.
Yang et al identified the molecular changes that inhib-
ited BCR-dependent NF-κB stimulation in the activated 
B cell-like (ABC) type of diffuse large B cell lymphoma (DLBCL), 
using SMAC mimetics. The researchers used the CRISPR 
system to demonstrate the specificity of SMAC mimetics, 
particularly in lymphoma subtypes and to show that SMAC 
mimetics prevent the recruitment of LUBAC ligase or BCL10 to 
the CBM complex (CARD11-MALT1-BCL10) and the existing 
redundancy between cIAPs (163).
On the other hand, the CRISPR approach seems to be a 
beneficial therapeutic tool in cancer types originating from 
viruses. In particular, it has been shown that the CRISPR 
system can combat oncolytic viruses by removing viral 
oncogenes or targeting genes responsible for viral genome 
maintenance and replication. For example, the CRISPR 
genome engineering tool has emerged as a great therapeutic 
option in patients infected with hepatitis B virus (HBV), which 
has life-threatening consequences, such as cirrhosis and most 
likely, hepatocellular carcinoma (164). The attack against 
the HBV virus was demonstrated through the suppression 
of HBV antigen expression in mice deficient for cccDNA, 
via the CRISPR system (165). Recently, another application 
of the CRISPR method against the HBV virus was shown to 
eliminate the recombinant form of cccDNA that causes viral 
persistence (166). In the context of hepatic defects caused 
by infections, nuclease-deficient FnCas9 has been reported 
to hinder the synthesis of HCV protein upon engagement of 
sgRNAs in the genome (167).
The Epstein-Barr Virus (EBV), which is related to an 
increased incidence of lymphomas, such as Burkitt lymphoma, 
Hodgkin's lymphoma, non-Hodgkin's lymphoma, as well as 
nasopharyngeal carcinoma, constitutes another example of a 
virus causing severe infections in humans. The modification 
of Burkitt lymphoma cells mediated by Cas9 nuclease has 
resulted in the cessation of viral replication and cell prolifera-
tion (168). Notably, the CRISPR system has also been shown 
to disrupt the HPV virus genes in both ‘in vitro’ and ‘in vivo’ 
xenograft models (169).
10. The CRISPR system against HIV infection
Antiretroviral therapy (ART) has thus far been used to eliminate 
infections caused by HIV, but without the anticipated outcomes. 
The disadvantages that render ART ineffective include admin-
istration for a prolonged period of time, the appearance of 
transient results in patients and the incidence of several side-
effects. Nonetheless, adoptive T cell therapy has been applied 
as a therapeutic option against cytomegalovirus (CMV) and 
EBV (158,170,171). When it comes to therapeutic strategies 
against human immunodeficiency virus (HIV), three promising 
therapies have been postulated thus far: i) Remodeling of the 
immune response through the enhancement of HIV-infected 
cell awareness and not via the recruitment of a large number of 
T cells, so that T cells can boost the response of other immu-
nological populations; ii) increasing the action and endurance 
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of T cells; and iii) triggering the immune system to develop 
memory cells, since HIV escapes immune mechanisms through 
viral quasispecies (vQS) or via mutagenesis at specific epit-
opes (Fig. 5). In principle, the memory T cell population can be 
triggered to create viral particles upon interruption of antiviral 
therapy, in the sense that HIV can be managed through an edited 
reservoir of memory T cells.
The remodeling of the immune response can be achieved 
by three different methods, all of which are aimed at 
expanding the compartment of HIV-specific T cells. These 
methodologies also attempt to refine the immune response 
against HIV by providing either mono-specific T cells or 
poly-specific T cells or modified T cells. In this context, 
HIV-directed T cells, activated by cytokines, have been used 
as a shield against HIV (171). However, mono-specific T cell 
expansion has proven to be insufficient against HIV, as the 
virus can circumvent the host immune system. Clinical studies 
have demonstrated that CD8+ T cells can be directed towards 
HLA A2 epitopes, thus eliciting responses against gp120, 
p17, p24 and Nef (172) or CD8+ T cells specific for Gag, in 
conditions that included OKT3 and IL-2 (173), without causing 
any differences in the viral load. At the same time, another 
clinical study reported no significant changes in the viral load 
using T cells specific for HIV: Gag p17-8 SLYNTVATL and 
Pol VIYQYMDDL (174). It was also postulated that the cure 
of HIV patients was unresolved due to the transient nature and 
the narrowed efficiency of T cells. Notably, the importance of 
increasing the persistence and efficacy of the immune response 
against HIV was highlighted.
An infusion of ‘poly-specific T cells’ that recognize 
different HIV antigens has also been employed to eliminate 
the HIV virus. Specifically, ‘polyclonal HIV-specific T cells 
were stimulated following exposure to multiple HIV antigens, 
even upon non-immunodominant epitopes. Additionally, the 
poly-specific T cells were concentrated without any require-
ment of class presentation, contributing to a broader range of 
therapeutic implementation. In the clinical setting, broadly-
specific cytotoxic T cells (HXTCs) were constructed to exhibit 
immune reactions with Gag, Nef and Pol epitopes and resulted 
in eradication of HIV replication (175). The beneficial effect of 
HXTCs was also validated in HIV-positive individuals with 
hematological perturbations (176). The results of the clinical 
trials have been registered (https://clinicaltrials.gov/). The 
implantation of multi-antigen T cell clones against HIV is 
currently being studied in a clinical trial (NCT02208167) (177).
Another promising approach is altering the genetic 
properties of T cells, i.e., equipping them with artificial 
TCRs or CARs that are composed of an extracellular region 
responsible for recognition of HIV antigens and an activation-
domain (178,179). Both types of receptors are modified in such 
a manner that they bind epitopes, apart from the individual 
HLA type of each patient, thus enhancing the therapeutic 
potential of the approach. The distinguishable characteristic of 
artificial TCRs is their crosstalk with a broad range of epitopes, 
thus aiding in the design of specific immune responses against 
certain epitopes and their interaction with crude viral proteins, 
irrespective of the patient's HLA type. Of note, a clinical study 
conducted in 2008 which included modified T cells loaded 
with specific SL9 TCRs, demonstrated the attenuation of HIV 
levels in immunodeficient mice (NOD/scid/IL-2Rγcnul) (180).
It should be noted, however, that the modified T cells were 
loaded with TCR receptors recognizing HLA-A*02 restricted 
P17 epitope SLYNTVATL (A2-SL9), which are related to 
depletion of HIV in chronic infection (180), thereby helping to 
overcome the immune escape exhibited by some HIV variants. 
Respectively, the hallmarks of CARs that distinguish them 
from TCRs are their ability to provide long-term protection 
without side-effects and their low immunogenicity. T cells 
were constructed to include a CAR receptor comprised from 
a CD4 extracellular domain that recognizes the Env glycopro-
tein of HIV and the intracellular signaling domain, termed 
‘CD4zeta-modified T cells’. When such modified T cells were 
used in a clinical trial (NCT01013415) in distinct phases, they 
produced very exciting results with regards to specified immu-
nity and persistence of T cells against HIV, in combination 
with a reduction of the HIV burden (181,182).
As a second immunological approach, it was observed that 
CD4+ T cells are recruited at the site of infection, supporting the 
presence and persistence of cytotoxic T cells against HIV (183). 
Specifically, the complex assembled between CD4 and MHCII 
determined the response of T helper cells to antigen and orches-
trated a complete immune response mediated by T CD8+ cells. 
In the same context, gene editing strategies have been employed 
to abolish the entry of HIV in an organism, via eradication 
of its receptors. For example, it was previously demonstrated 
that a patient who received a transplant with mutated CCR5 
receptor at delta 32 position was cured, acquiring natural HIV 
resistance (184). Initially, the elimination of HIV coreceptors 
was achieved using ZNFs that combined Fok1 endonuclease 
with the DNA-binding zinc finger domain (185). At the pre-
clinical level, ZNFs have been employed for the disruption of 
HIV coreceptors (CXCR4 or CCR5) (186) at a successful rate, 
allowing the implementation of ZNF nucleases against HIV 
in the clinical setting (187). However, the use of ZNFs against 
HIV infection was hindered by the potential cross-reactivity 
and side-effects (188). Compared to ZNFs, the CRISPR system 
was shown to be more beneficial due to its multiplex capacity 
to disrupt the function of both HIV coreceptors with amenable 
side-effects (189). In addition, Kaminski et al demonstrated 
another convincing method through which persistent expres-
sion of Cas9 can impede HIV-1 replication in infected CD4+ 
T cells and protect HIV-1-infected T cells against new infec-
tion. Specifically, it was shown that the excision of the genomic 
regions of the HIV-1 promoter that are located at the 5' long 
terminal repeat (LTR) in 2D10 CD4+ T cells, was responsible 
for HIV eradication (190).
In an attempt to increase the persistence of T cells, the 
latter method employed enrichment of T cells with the memory 
phenotype so as to combat every new infection more rapidly 
and efficiently. Apart from the infusion of T memory cells in 
the cancer setting (191), the T cell memory reservoir has been 
employed against HIV in the clinical setting (192). To sum up, 
T cell engineering holds great promise in the therapeutic 
management of HIV in the absence of ART.
11. Challenges associated with the CRISPR-based gene 
method and alternative methods
For the successful implementation of a therapeutic approach 
based on the CRIPSR method, the existing challenges include 
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increasing the specificity of CRISPR system, as well as deliv-
ering Cas9 nuclease and its sgRNAs without side-effects. In 
this session, we analyze proposed methods with which to 
circumvent these difficulties.
Challenge 1: Delivery. First, the ‘ex vivo’ delivery of Cas9 
nuclease and its sgRNAs has been reported to be achieved with 
the use of plasmids or classical viral methods (adenovirus, lenti-
virus, adeno-associated virus or retrovirus). In parallel, Cas9 
nuclease has been shown to be delivered through non-viral 
methods, including cationic lipids or nanoparticle encapsula-
tion or electroporation (193) or microinjection (194,195). In 
these cases, Cas9 nuclease and its gRNA are delivered in the 
form of RNPs, resulting in a long-term response.
In the case of plasmids, the transferred components are 
inserted into the nuclear area, thus ensuring that delivery is 
restricted to dividing cells and the danger of insertional muta-
genesis usually associated with viruses is eliminated (196). 
Regarding the ‘ex vivo’ delivery of the CRISPR system 
constituents, the iTOP technique and mechanical cell derange-
ment are the current methods. In the case of mechanical cell 
deformation, membranes are temporally disturbed, following 
the collection of cell samples in microfluidic devices, allowing 
the passive diffusion of substances in non-nuclear regions. 
Single-strand DNA and plasmids have been reported to 
employ the mechanism of delivery (197). In the iTOP method, 
macromolecules are delivered into cells via micropinocy-
tosis and using propanebetaine with minimal toxicity (198). 
In addition, Ha et al have presented an innovative way of 
delivery through Poly-sgRNA/siRNA nanoparticles, in order 
to disrupt gene expression (199). The principle in using these 
nanoparticles is based on the assembly of siRNA (substrate 
of Dicer) and sgRNAs, which are cleaved through the action 
of Dicer following rolling circle transcription (RCT). The 
advantages are as follows: i) Minimal toxicity; ii) nanopar-
ticle strength and stability; and iii) single administration of 
components to ensure the permanent disarrangement of target 
gene expression (199). Other delivery methods have been 
reported to be involved in the ‘in vivo’ transfer of constituents 
of the CRISPR system. The first includes the encapsula-
tion of Cas9 nuclease and the appropriate sgRNAs in DNA 
nanoclews, which constitute DNA nanoparticles constructed 
by rolling circle amplification (200). DNA nanoclews have 
been postulated as a suitable choice for delivery as they 
offer a high intrusion of DNA nanoparticle delivery into 
cells (200). A different rationale has been suggested that fuses 
the C-terminal end of Cas9 nuclease with a ‘nona-arginine’ 
based cell penetrating peptide (CPP), thereby recruiting the 
appropriates gRNA (201). In both cases, the positive charge 
of particles is responsible for the direct entry of the CRISPR 
system in cells.
Typically, Cas9 nuclease and sgRNA can be delivered 
either as DNA or RNA, and both can be packaged into viral 
vectors. The advantage of viral vectors in transferring the 
CRISPR system is attributed to their ability to regulate gene 
expression in a spatial-temporal manner, given that a viral 
vector has the selected promoter to guide transcription of 
Cas9 and its sgRNA, even though insertional mutagenesis and 
immunogenic responses can still occur (202). Adenoviruses 
have been proposed as the safest viral method in transferring 
the CRISPR components, due to their serotype specificity and 
low immunogenicity, despite their low packaging capacity. 
For example, recent data have highlighted the AAV9 vector 
as the ideal method in transferring the CRISPR components 
in the Duchenne dystrophin gene (81,203,204). In another 
study, Gomez et al engineered adeno-associated (AAV) virus 
exposing phytochrome interacting factor 6 motifs (PIF6), to 
interact with phytochrome B (PhyB) factor in response to 
red light, thus attaining high nuclear translocation of virus in 
cells and implying a proposal of transferring CRISPR system 
through adeno-associated virus (205). Further on, Ran et al 
used an alternative version of Cas9 (SaCas9), which was 1 kb 
shorter in length than Cas9 nuclease, and was packaged into the 
AAV serotype 8 vector. The deficiency of ApoB and PSCK9 
was determined to be at a rate of 40% in hepatocytes (206).
In order to avoid the danger of insertional mutagenesis, 
cationic lipid nanoparticles (LNPs) have been suggested 
as an extraordinary non-immunogenic selection for the 
intracellular delivery of anionic molecules that can be encap-
sulated (207,208). The LNPs can specifically transfer their load 
in a cell-dependent manner for a long period, taking advantage 
of the charge, the hydrophobicity/hydrophilicity of the load 
and biocompatibility/clearance (207). For example, LNPs have 
been devised to contain the lipid-like material C12-200 for 
the successful introduction of modifications in hepatocytes, 
thus highlighting the CRISPR constructs and the homology-
directed repair mechanism. The efficacy of gene repair with 
this method appears to be higher than that accomplished with 
the use of viruses (39).
Future efforts should focus on delivering the CRISPR 
components in cell types other than hepatocytes, including 
non-dividing cells and stem cells, in an attempt to increase 
intake of the CRISPR components and to pave the road for 
new therapeutic interventions. In conjunction with studies 
on materials science, other delivery methods could be imple-
mented in order to boost the efficiency of the CRISPR system 
and to circumvent the side-effects induced by the classical 
means of delivery.
Challenge 2: Methods for enhancing Cas9 nuclease activity. 
Even though most efforts are currently focused on exploring 
the molecular mechanisms underlying the fundamental 
biological processes or on improving the therapeutic outcome 
of a number of diseases, research teams explore several 
options for the validation or enhancement of Cas9 nuclease 
activity. The precision of the CRISPR system can be increased 
by modifying Cas9 nuclease.
To validate Cas9 nuclease activity, several sequencing 
methods, in conjunction with in silico prediction programs, 
have been extensively used, for the detection of the off-target 
effects in a genome-wide high sensitive manner. Specifically, 
the efficacy of Cas9 has been confirmed by integrase-
defective lentiviral vector capture (IDLV) (37,209), linear 
amplification-mediated PCR (LAM-PCR), high-throughput 
genome-wide translocation sequencing (HTGTS) (210), 
genome-wide unbiased identification of DSBs enabled 
by sequencing (GUIDE-seq) (211,212), next-generation 
sequencing (BLESS) (213) using in situ adapter ligation and 
digested genome sequencing (Digenome-seq) (214). The 
above-mentioned tools have been generated with the notion 
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in mind that potential mismatches can be created between 
sgRNA and complementary DNA sequence. These tech-
niques have enriched our knowledge in bypassing unintended 
effects mediated by CRISPR system and in determining the 
implementation of the advanced engineered toolbox. In other 
words, the challenging nature of the CRISPR system has led to 
enhancement of Cas9 nuclease precision.
12. Ways to circumvent the off-target effects of the CRISPR 
system
To date, two methods have been reported to eliminate the 
off-target cleavage effects generated by Cas9 nuclease, either 
by augmenting the specificity or by decreasing the duration of 
Cas9 nuclease action.
To enhance the specificity, a first approach is based on 
truncating the guide RNA from 20 nucleotides to 17 or 18 
nucleotides in the genomic region where RNA creates 
complementary bonds, away from the PAM sequence, 
while at the same time, Cas9 nuclease retains its activity at 
desired genomic sequences (215,216). The application of the 
aforementioned approach has demonstrated the reduction 
of random effects (18,37,215,217,218). The validity of the 
method (using truncated sgRNA) has been confirmed by 
GUIDE-seq or targeted deep sequencing in human cells (216). 
One potential explanation for the above-mentioned property 
of the CRISPR system lies on reducing the excess energy that 
is released by RNA-DNA complementarity, thereby rendering 
Cas9 nuclease to be very specific on cleavage events. Another 
method for elevating Cas9 specificity is based on using two 
Figure 5. Modified T cell fight against immune HIV variants. In general, T cells recognize and eliminate the HIV-infected cells. However, some cells express 
variant HIV epitopes that help them to accomplish immune escape. In this context, the CRISPR-edited infected cells can revert to their normal state, recruiting 
T cells in order to abrogate the HIV challenge. HIV, human immunodeficiency virus; CRISPR, clustered regularly interspaced short palindromic repeats.
Figure 6. (A) Generation of genetically modified mouse models harboring either eliminations or insertions or chromosome translocations through transfecting 
Cas9 with single or multiple sgRNAs. (B) Generation of screens using Cas9 and pool of sgRNAs libraries. (C) Targeted mutagenic screens through viral 
delivery of Cas9 and targeted sgRNA libraries. Generating organoids to predict the response of patient to administration of potential drugs. sgRNA, single-chi-
meric guide RNA; Cas9, CRISPR-associated protein 9; iPSCs, induced pluripotent stem cells.
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additional guanine nucleotides in the 5' end of the guide 
sequence (36,217). The underlying mechanism of action 
remains elusive, but one can envisage that disorganization of 
the association network between Cas9 nuclease and the 5' end 
of the sgRNA is responsible for reducing the off-target effects 
mediated by Cas9. In an attempt to boost the Cas9 precision 
and to minimize the random non-specific cleavage effects, 
paired Cas9 nickases have been reportedly used. The nickases 
introduce a single-strand cut (nick) with the same specificity 
as a regular Cas9 nuclease and a pair of nickases are used to 
initiate double nicks in each DNA strand, using two separate 
sgRNAs. The major difference is when two Cas9 nickases are 
used, long overhangs are produced on each of the cleaved ends, 
instead of blunt ends. Cas9 nickase is also distinguishable from 
Cas9 nuclease because the former has an inactivated catalytic 
domain (either in RuvC or HNH part) among its six domains: 
REC I, REC II, Bridge Helix, PAM Interacting, HNH and 
RuvC (219). Specifically, a D10A replacement at RuvC domain 
or H840A substitution at HNH takes place, producing a highly 
specific DNA-binding complex. A characteristic example 
includes the assembly of one sgRNA with Cas9 nickase, 
resulting in the reduction of off-target effects in human 
cells (220). Nevertheless, Cas9 nickase has not been reported 
as particularly effective in introducing DSBs, as compared to 
Cas9 nuclease, since Cas9 nickase has been shown to insert 
point mutations in anticipated target sites (220,221).
Another approach for minimizing side-effects is to use dimer-
ized factors. Dimerized proteins, in particular, use synergistic 
energy to achieve the desired efficiency. For example, dCas9 
was combined with a dimerization-dependent FokI nuclease 
domain, resulting in a complex named RNA-guided FokI-dCas9 
nuclease (RFN) (222). In the same context, RNA-guided FokI-
dCas9 nuclease (RFN) has been used with truncated sgRNA at 
the 5' end, attaining the best specificity of Cas9 nuclease (223). 
Finally, it has been shown that Cas9 nuclease precision can 
be improved by modulating Cas9 with alanine replace-
ments at four residues (25). Of note, the GUIDE-sequencing 
method (GUIDE-seq) has provided convincing evidence that 
the Cas9 version containing the alanine substitutions is far more 
specific than the unmodified Cas9 nuclease (224), preventing 
non-targeted cleavage events at the DNA sequence.
Hou et al isolated a different form of Cas9 nuclease from 
Neisseria meningitidis (NmCas9), which exerts its effects very 
efficiently and with great specificity (225). In-depth analyses 
have reported that NmCas9 binds a 24 nt crRNA, providing 
superior specificity over the previous 20 nt crRNA used by 
Cas9 derived from Streptococcus pyogenes. Notably, the PAM 
sequence of NmCas9 comprises an either 5'-NNNNGATT-3' 
or 5'-NNNNGCTT-3' genomic sequence, through which it 
accomplishes efficient DNA cleavage. As would be expected, 
the long PAM sequence employed by NmCas9 confers high 
specificity. The efficiency offered by NmCas9 is higher (60%) 
in hESCs and iPSCs compared to that offered by other nucle-
ases and in parallel its use can be expanded to trace cell fate 
of rare cells (226).
13. Conclusion
The rationale based on which the prokaryotic viral defense 
mechanism is converted to the eminent engineering approach 
underscores the significance of basic science research. We 
conclude that the CRISPR system is unique and capable of 
providing therapeutic applications using stem cells or organ-
oids of different origins. The utility of the CRISPR system 
seems to be beneficial in the genetic screening for cancer gene 
validation/discovery. The multilayered characterization of new 
targets will give comprehensive insights into the therapeutic 
potential of the particular system, thus guiding its appropriate 
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